Dai Nippon Printing Co.,Ltd. has jointly established the joint venture TriNebula Cell Tech with NEXEL and CMIC Pharma Science, aiming to expand globally products including cardiomyocytes derived from human iPS cells.
Dai Nippon Printing Co.,Ltd. jointly invested with NEXEL Co., Ltd. and CMIC Pharma Science to establish the joint venture TriNebula Cell Tech on 9 October 2026. TriNebula will handle the marketing for global expansion of products including cardiomyocytes derived from human iPS cells in the field of evaluation methods that replace or complement animal testing. Under a licensing agreement with NEXEL, DNP will manufacture cardiomyocytes and aims to build a global manufacturing and sales structure based on market needs identified by TriNebula.
The company says demand for technologies that replace animal testing is increasing in response to growing interest in animal welfare and developments in regulations and guidelines in various countries. Cardiomyocytes derived from human iPS cells are expected to be used in efficacy and safety assessments.
According to the company profile, TriNebula Cell Tech is headquartered in Shinjuku-ku, Tokyo, its representative director and president is Kajimura Yoichi (梶村 陽一), its capital is ¥50 million, and its date of establishment is 9 October 2026. Its business comprises marketing, sales promotion and related activities for iPS cell-related products.
Going forward, the company aims to expand drug discovery research and safety assessments of promising drug candidates through the marketing of iPS cell-related products, including cardiomyocytes. It is considering commercializing new products and services by combining DNP’s manufacturing and quality-control capabilities, NEXEL’s research and development capabilities, and CMIC Pharma Science’s experience in contract testing.